BioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 50 cents per share.
Reported revenue was zero; analysts expected zero.
BioCardia Inc's reported EPS for the quarter was a loss of 40 cents.
The company reported a quarterly loss of $2.05 million.
BioCardia Inc shares had fallen by 8.2% this quarter and lost 17.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 163.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 88.5% above its last closing price of $1.79
This summary was machine generated from LSEG data August 11 at 02:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2025 | -0.50 | -0.40 | Beat |
Mar. 31 2025 | -0.39 | -0.59 | Missed |
Dec. 31 2024 | -0.62 | -0.25 | Beat |
Sep. 30 2024 | -1.19 | -0.61 | Beat |